User login
THURSDAY, MARCH 22, 2018
MORNING SESSION
Henry A. Nasrallah, MD, Saint Louis University, began the conference by presenting the latest information on several recent advances in schizophrenia, including genetic and nongenetic etiologies, abnormalities in the mitochondria and microglia activation leading to oxidative stress and inflammation, and emerging treatment and prevention strategies.
Next, Dr. Nasrallah described how to identify and treat the schizophrenia prodrome. He covered frequently used assessment tools, neuroimaging findings, and the consequences of delayed treatment.
Michael J. Gitlin, MD, University of California, Los Angeles, described current uses of stimulants for treating psychiatric disorders. He covered their use for attention-deficit/hyperactivity disorder (ADHD), unipolar depression, bipolar depression, and other conditions.
AFTERNOON SESSION
The afternoon began with Donald W. Black, MD, University of Iowa, providing an update on obsessive-compulsive disorder and related conditions. He reviewed the efficacy of several treatments, including pharmacologic and behavior therapies.
Next, Dr. Gitlin covered the potential relationships between depression and several comorbid disorders, including borderline personality disorder, schizophrenia, alcohol use disorders, and other mental illnesses.
Dr. Black presented an update on hoarding. He detailed the differential diagnosis, clinical characteristics, and clinical management strategies for addressing this challenging disorder.
Tracy D. Gunter, MD, Indiana University, identified common legal issues encountered by clinical psychiatrists and the challenges they pose. She described how to develop strategies for approaching common clinical problems while minimizing medicolegal risk.
Continue to: Friday sessions
FRIDAY, MARCH 23, 2018
MORNING SESSION
To start Day 2, Marlene P. Freeman, MD, Massachusetts General Hospital, focused on bipolar disorder in women. She described factors to consider when treating a pregnant woman with this illness.
Dr. Freeman continued with a unique session that covered topics attendees had requested in advance. These included the relationship between polycystic ovarian syndrome and depression, infertility and psychiatry, and nonpharmacologic treatments for depression in pregnant women.
Dr. Gunter presented a session on correctional psychiatry, including the major differences between office-based clinical psychiatry and on-site correctional psychiatry and some of the challenges of working in this setting.
AFTERNOON SESSION
Robert M. McCarron, DO, University of California, Irvine, described how to treat psychiatric patients who have chronic pain. He covered the responsible use of opioid analgesics and how to diagnose and treat somatic symptom disorders.
Anthony L. Rostain, MD, MS, University of Pennsylvania, discussed practical approaches to managing ADHD comorbidities. He outlined pharmacologic and psychosocial strategies for patients who have ADHD and comorbid anxiety, depression, substance use disorders, and certain medical conditions.
Dr. McCarron continued the afternoon with a session that focused on preventing endocrine and cardiovascular disorders. He provided prevention and diagnostic measures for metabolic syndrome and tips for preventing and diagnosing dyslipidemia and diabetes.
Dr. Rostain continued by presenting a session on autistic spectrum disorders in adults. He covered clinical features, common comorbidities, and medication management.
The day concluded with a special AACP Members’ Reception.
Continue to: Saturday session
SATURDAY, MARCH 24, 2018
MORNING SESSION
George T. Grossberg, MD, Saint Louis University, began the day by covering the neuroanatomic and neurochemical substrates of behavioral symptoms in Alzheimer’s disease and their implications for treatment. He described behavioral and pharmacologic treatments for agitation and behavioral symptoms in patients with dementia.
Next came a special keynote address by Mark A. Frye, MD, Mayo Clinic, Rochester, titled Ketamine Update: What Should Clinicians Know and Expect.
Stephen B. Levine
Dr. Grossberg presented on aging, traumatic brain injury, chronic traumatic encephalopathy, and Alzheimer’s disease. He covered the sequelae, prevention, and treatment of these conditions.
Dr. Levine concluded the conference by providing a clinical overview of transgender issues. He included a discussion of the role mental health professionals should play in gender affirmation.
Continue to: SPONSORS AND SUPPORTERS
SPONSORS AND SUPPORTERS
- Admera Health
- Alkermes
- Alpha Genomix Laboratories
- Alzheimer's Association
- Amita Health Alexian Brothers Behavioral Health Hospital
- Aurora Health Care
- Bellin Psychiatric Center
- GeneSight
- Genoa Telepsychiatry
- Howard Brown Health
- Jaymac Pharmaceuticals
- Legally Mine
- Professional Risk Management Services, Inc.
- Pine Rest Christian Mental Health Services
- Sunovion Pharmaceuticals, Inc.
- Supernus Pharmaceuticals, Inc.
- Takeda Pharmaceuticals U.S.A., Inc. / Lundbeck
- U.S. Army Medicine Civilian Corps
- Wexford Health Sources
- Wolters Kluwer
The meeting organizers acknowledge the support provided by our sponsors. Determination of educational content for this program and the selection of speakers are responsibilities of the program director and co-chairs. Sponsors and supporters did not have input in these areas.
THURSDAY, MARCH 22, 2018
MORNING SESSION
Henry A. Nasrallah, MD, Saint Louis University, began the conference by presenting the latest information on several recent advances in schizophrenia, including genetic and nongenetic etiologies, abnormalities in the mitochondria and microglia activation leading to oxidative stress and inflammation, and emerging treatment and prevention strategies.
Next, Dr. Nasrallah described how to identify and treat the schizophrenia prodrome. He covered frequently used assessment tools, neuroimaging findings, and the consequences of delayed treatment.
Michael J. Gitlin, MD, University of California, Los Angeles, described current uses of stimulants for treating psychiatric disorders. He covered their use for attention-deficit/hyperactivity disorder (ADHD), unipolar depression, bipolar depression, and other conditions.
AFTERNOON SESSION
The afternoon began with Donald W. Black, MD, University of Iowa, providing an update on obsessive-compulsive disorder and related conditions. He reviewed the efficacy of several treatments, including pharmacologic and behavior therapies.
Next, Dr. Gitlin covered the potential relationships between depression and several comorbid disorders, including borderline personality disorder, schizophrenia, alcohol use disorders, and other mental illnesses.
Dr. Black presented an update on hoarding. He detailed the differential diagnosis, clinical characteristics, and clinical management strategies for addressing this challenging disorder.
Tracy D. Gunter, MD, Indiana University, identified common legal issues encountered by clinical psychiatrists and the challenges they pose. She described how to develop strategies for approaching common clinical problems while minimizing medicolegal risk.
Continue to: Friday sessions
FRIDAY, MARCH 23, 2018
MORNING SESSION
To start Day 2, Marlene P. Freeman, MD, Massachusetts General Hospital, focused on bipolar disorder in women. She described factors to consider when treating a pregnant woman with this illness.
Dr. Freeman continued with a unique session that covered topics attendees had requested in advance. These included the relationship between polycystic ovarian syndrome and depression, infertility and psychiatry, and nonpharmacologic treatments for depression in pregnant women.
Dr. Gunter presented a session on correctional psychiatry, including the major differences between office-based clinical psychiatry and on-site correctional psychiatry and some of the challenges of working in this setting.
AFTERNOON SESSION
Robert M. McCarron, DO, University of California, Irvine, described how to treat psychiatric patients who have chronic pain. He covered the responsible use of opioid analgesics and how to diagnose and treat somatic symptom disorders.
Anthony L. Rostain, MD, MS, University of Pennsylvania, discussed practical approaches to managing ADHD comorbidities. He outlined pharmacologic and psychosocial strategies for patients who have ADHD and comorbid anxiety, depression, substance use disorders, and certain medical conditions.
Dr. McCarron continued the afternoon with a session that focused on preventing endocrine and cardiovascular disorders. He provided prevention and diagnostic measures for metabolic syndrome and tips for preventing and diagnosing dyslipidemia and diabetes.
Dr. Rostain continued by presenting a session on autistic spectrum disorders in adults. He covered clinical features, common comorbidities, and medication management.
The day concluded with a special AACP Members’ Reception.
Continue to: Saturday session
SATURDAY, MARCH 24, 2018
MORNING SESSION
George T. Grossberg, MD, Saint Louis University, began the day by covering the neuroanatomic and neurochemical substrates of behavioral symptoms in Alzheimer’s disease and their implications for treatment. He described behavioral and pharmacologic treatments for agitation and behavioral symptoms in patients with dementia.
Next came a special keynote address by Mark A. Frye, MD, Mayo Clinic, Rochester, titled Ketamine Update: What Should Clinicians Know and Expect.
Stephen B. Levine
Dr. Grossberg presented on aging, traumatic brain injury, chronic traumatic encephalopathy, and Alzheimer’s disease. He covered the sequelae, prevention, and treatment of these conditions.
Dr. Levine concluded the conference by providing a clinical overview of transgender issues. He included a discussion of the role mental health professionals should play in gender affirmation.
Continue to: SPONSORS AND SUPPORTERS
SPONSORS AND SUPPORTERS
- Admera Health
- Alkermes
- Alpha Genomix Laboratories
- Alzheimer's Association
- Amita Health Alexian Brothers Behavioral Health Hospital
- Aurora Health Care
- Bellin Psychiatric Center
- GeneSight
- Genoa Telepsychiatry
- Howard Brown Health
- Jaymac Pharmaceuticals
- Legally Mine
- Professional Risk Management Services, Inc.
- Pine Rest Christian Mental Health Services
- Sunovion Pharmaceuticals, Inc.
- Supernus Pharmaceuticals, Inc.
- Takeda Pharmaceuticals U.S.A., Inc. / Lundbeck
- U.S. Army Medicine Civilian Corps
- Wexford Health Sources
- Wolters Kluwer
The meeting organizers acknowledge the support provided by our sponsors. Determination of educational content for this program and the selection of speakers are responsibilities of the program director and co-chairs. Sponsors and supporters did not have input in these areas.
THURSDAY, MARCH 22, 2018
MORNING SESSION
Henry A. Nasrallah, MD, Saint Louis University, began the conference by presenting the latest information on several recent advances in schizophrenia, including genetic and nongenetic etiologies, abnormalities in the mitochondria and microglia activation leading to oxidative stress and inflammation, and emerging treatment and prevention strategies.
Next, Dr. Nasrallah described how to identify and treat the schizophrenia prodrome. He covered frequently used assessment tools, neuroimaging findings, and the consequences of delayed treatment.
Michael J. Gitlin, MD, University of California, Los Angeles, described current uses of stimulants for treating psychiatric disorders. He covered their use for attention-deficit/hyperactivity disorder (ADHD), unipolar depression, bipolar depression, and other conditions.
AFTERNOON SESSION
The afternoon began with Donald W. Black, MD, University of Iowa, providing an update on obsessive-compulsive disorder and related conditions. He reviewed the efficacy of several treatments, including pharmacologic and behavior therapies.
Next, Dr. Gitlin covered the potential relationships between depression and several comorbid disorders, including borderline personality disorder, schizophrenia, alcohol use disorders, and other mental illnesses.
Dr. Black presented an update on hoarding. He detailed the differential diagnosis, clinical characteristics, and clinical management strategies for addressing this challenging disorder.
Tracy D. Gunter, MD, Indiana University, identified common legal issues encountered by clinical psychiatrists and the challenges they pose. She described how to develop strategies for approaching common clinical problems while minimizing medicolegal risk.
Continue to: Friday sessions
FRIDAY, MARCH 23, 2018
MORNING SESSION
To start Day 2, Marlene P. Freeman, MD, Massachusetts General Hospital, focused on bipolar disorder in women. She described factors to consider when treating a pregnant woman with this illness.
Dr. Freeman continued with a unique session that covered topics attendees had requested in advance. These included the relationship between polycystic ovarian syndrome and depression, infertility and psychiatry, and nonpharmacologic treatments for depression in pregnant women.
Dr. Gunter presented a session on correctional psychiatry, including the major differences between office-based clinical psychiatry and on-site correctional psychiatry and some of the challenges of working in this setting.
AFTERNOON SESSION
Robert M. McCarron, DO, University of California, Irvine, described how to treat psychiatric patients who have chronic pain. He covered the responsible use of opioid analgesics and how to diagnose and treat somatic symptom disorders.
Anthony L. Rostain, MD, MS, University of Pennsylvania, discussed practical approaches to managing ADHD comorbidities. He outlined pharmacologic and psychosocial strategies for patients who have ADHD and comorbid anxiety, depression, substance use disorders, and certain medical conditions.
Dr. McCarron continued the afternoon with a session that focused on preventing endocrine and cardiovascular disorders. He provided prevention and diagnostic measures for metabolic syndrome and tips for preventing and diagnosing dyslipidemia and diabetes.
Dr. Rostain continued by presenting a session on autistic spectrum disorders in adults. He covered clinical features, common comorbidities, and medication management.
The day concluded with a special AACP Members’ Reception.
Continue to: Saturday session
SATURDAY, MARCH 24, 2018
MORNING SESSION
George T. Grossberg, MD, Saint Louis University, began the day by covering the neuroanatomic and neurochemical substrates of behavioral symptoms in Alzheimer’s disease and their implications for treatment. He described behavioral and pharmacologic treatments for agitation and behavioral symptoms in patients with dementia.
Next came a special keynote address by Mark A. Frye, MD, Mayo Clinic, Rochester, titled Ketamine Update: What Should Clinicians Know and Expect.
Stephen B. Levine
Dr. Grossberg presented on aging, traumatic brain injury, chronic traumatic encephalopathy, and Alzheimer’s disease. He covered the sequelae, prevention, and treatment of these conditions.
Dr. Levine concluded the conference by providing a clinical overview of transgender issues. He included a discussion of the role mental health professionals should play in gender affirmation.
Continue to: SPONSORS AND SUPPORTERS
SPONSORS AND SUPPORTERS
- Admera Health
- Alkermes
- Alpha Genomix Laboratories
- Alzheimer's Association
- Amita Health Alexian Brothers Behavioral Health Hospital
- Aurora Health Care
- Bellin Psychiatric Center
- GeneSight
- Genoa Telepsychiatry
- Howard Brown Health
- Jaymac Pharmaceuticals
- Legally Mine
- Professional Risk Management Services, Inc.
- Pine Rest Christian Mental Health Services
- Sunovion Pharmaceuticals, Inc.
- Supernus Pharmaceuticals, Inc.
- Takeda Pharmaceuticals U.S.A., Inc. / Lundbeck
- U.S. Army Medicine Civilian Corps
- Wexford Health Sources
- Wolters Kluwer
The meeting organizers acknowledge the support provided by our sponsors. Determination of educational content for this program and the selection of speakers are responsibilities of the program director and co-chairs. Sponsors and supporters did not have input in these areas.
